Institutional members access full text with Ovid®

Share this article on:

Relation between serum monocyte chemoattractant protein-1 and coronary collateral development

Sahinarslan, Asifea; Kocaman, Sinan A.a; Topal, Saliha; Ercin, Ugurb; Bukan, Neslihanb; Yalcin, Ridvana; Timurkaynak, Timura

doi: 10.1097/MCA.0b013e32833fd29b
Pathophysiology and Natural History

Background The degree of coronary collateral development is not same in every patient with similar degree of coronary stenosis. In animal studies monocyte chemoattractant protein-1 (MCP-1) has been found to be related to collateral vessel development. In this study we investigated whether a higher serum MCP-1 level is related to better coronary collateral vessel development in patients with stable coronary artery disease.

Method Eighty-three patients with stable angina pectoris, who have at least one coronary stenosis equal to or greater than 70% at coronary angiography, were prospectively enrolled. Serum MCP-1 and vascular endothelial growth factor (VEGF) levels were studied. Coronary collateral development was graded according to the Rentrop method. Patients with grade 2–3 collateral developments were included in good collateral group and formed group I. The patients with grade 0–1 collateral developments were included in poor collateral group and formed group II.

Results The serum MCP-1 level was significantly higher in good collateral group (288±277 pg/ml vs. 132±64 pg/ml; P<0.001). There was also a positive correlation between serum MCP-1 level and Rentrop score (r=0.39, P<0.001). The patients in the good collateral group also had a significantly higher number of coronary arteries with significant stenosis (1.7±0.7 vs. 1.4±0.6, P=0.049), and higher VEGF levels (322±147 pg/ml vs. 225±161 pg/ml, P=0.007). In multivariate analysis, only serum MCP-1 level (P=0.014, odds ratio: 1.01, 95% confidence interval: 1.002–1.019) was independently related to good coronary collateral development.

Conclusion Higher serum MCP-1 level is related to better coronary collateral development.

aDepartments of Cardiology

bBiochemistry, School of Medicine, Gazi University, Ankara, Turkey

Correspondence to Dr Asife Sahinarslan, MD, Gazi Üniversitesi Hastanesi, Kardiyoloji Bolümü, Kat: 6 Beşevler/Ankara 06500, Turkey Tel: +90 312 2025624; fax: +90 312 2129012; e-mail: e-mail:asifesah@yahoo.com

Received June 2, 2010

Accepted August 17, 2010

© 2010 Lippincott Williams & Wilkins, Inc.